D. Boral Capital Downgrades Tevogen Bio (NASDAQ:TVGN) to Hold

Tevogen Bio (NASDAQ:TVGN) was downgraded by research analysts at D. Boral Capital from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, MarketBeat.com reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tevogen Bio in a research report on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $2.00.

Tevogen Bio Stock Performance

Shares of TVGN stock opened at $0.16 on Wednesday. The stock has a 50 day moving average price of $0.30 and a 200 day moving average price of $0.53. Tevogen Bio has a 52-week low of $0.14 and a 52-week high of $1.51. The firm has a market capitalization of $30.82 million, a P/E ratio of -0.82 and a beta of -0.76.

Hedge Funds Weigh In On Tevogen Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after acquiring an additional 152,572 shares during the period. Deutsche Bank AG raised its holdings in shares of Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in shares of Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after purchasing an additional 33,000 shares during the period.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.